Sam Shrivastava is an accomplished biotech entrepreneur, business strategist, and investor. In 2016, Sam founded Venn Therapeutics, a highly innovative drug discovery incubator. Under his visionary leadership as Chairman and CEO, a team of leading clinical immunotherapists and scientific inventors are developing a portfolio of novel, best-in-class integrin antibodies that are translating today’s most promising and innovative breakthroughs in cancer research into tomorrow’s life-saving treatments.

Mr. Shrivastava is also the founder and Chairman of Ibis Therapeutics, which uses artificial intelligence and machine learning to build small-molecule drugs and repurpose existing drugs. Ibis is currently working with a team of immunologists and virologists exclusively focused on COVID-19.

Mr. Shrivastava began his career in banking before founding his first company, Blackbird BioFinance, an immuno-oncology company focused on lung cancer. Blackbird was sold 14 months later to Cellular Biomedicine Group Inc. (NASDAQ: CBMG).

In all his endeavors, Mr. Shrivastava is committed to improving patient health outcomes and creating shareholder value through rigorous target selection, clinical and preclinical studies, antibody production management, and small molecule synthesis execution.

Mr. Shrivastava is the co-inventor on two provisional patents for small molecule discovery in immunology. He is a graduate of the High-Impact Cancer Research postgraduate certificate program at Harvard Medical School and an Associate Alum of Harvard Medical School.